Windsor Regional Cancer Centre

Running trials

• Recruiting

  Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

  NCT06182774· Phase 3· Source

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· Source

• Active, not recruiting

  PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer

  NCT04557501· Phase 3· Source

• Active, not recruiting

  Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

  NCT03055013· Phase 3· Source

• Active, not recruiting

  Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

  NCT03057106· Phase 2· Source

• Active, not recruiting

  Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

  NCT02506153· Phase 3· Source

• Active, not recruiting

  Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

  NCT02179086· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

  NCT02630693· Phase 2· Source

• Completed

  Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

  NCT02254278· Phase 2· Source